Wegovy may have highest ‘eye stroke’ and sight loss risk of semaglutide GLP-1 agonists
Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of ‘eye stroke’ (ischaemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side effect reports published in the British Journal of Ophthalmology.
The risk is almost 5 times higher with Wegovy than it is with Ozempic, and 3 times greater in men than it is in women, the analysis indicates.
Ischaemic optic neuropathy, or ION for short, is caused by inadequate/interrupted ...